CHU Reims, Unité d'Aide Méthodologique, 51100, Reims, France.
Department of Research and Public Health, Robert Debré Hospital, Reims University Hospitals, Rue du Général Koenig, 51092, Reims, France.
BMC Infect Dis. 2022 Jun 13;22(1):541. doi: 10.1186/s12879-022-07517-w.
The SARS-COV2 pandemic has been ongoing worldwide since at least 2 years. In severe cases, this infection triggers acute respiratory distress syndrome and quasi-systemic damage with a wide range of symptoms. Long-term physical and psychological consequences of this infection are therefore naturally present among these patients. The aim of this study was to describe the state of health of these patients at 6 (M6) and 12 months (M12) after infection onset, and compare quality-of-life (QOL) and fatigue at these time-points.
A prospective cohort study was set up at Reims University Hospital. Patients were clinically assessed at M6 and M12. Three scores were calculated to describe patient's status: the modified Medical Research Council score (mMRC) used to determine dyspnoea state, the Fatigue Severity Scale (FSS) and the Short Form 12 (SF12) that was carried out to determine the QOL both mentally and physically (MCS12 and PCS12). Descriptive analysis and comparison of scores between M6 and M12 were made.
120 patients completed both follow-up consultations. Overall, about 40% of the patients presented dyspnoea symptoms. The median mMRC score was 1 Interquartile ranges (IQR) = [0-2] at the two assessment. Concerning FSS scores, 35% and 44% of patients experienced fatigue at both follow-ups. The two scores of SF12 were lower than the general population standard scores. The mean PCS12 score was 42.85 (95% confidence interval (95% CI [41.05-44.65])) and mean MCS12 score of 46.70 (95% CI [45.34-48.06]) at 6 months. At 12 months, the mean PCS12 score was 42.18 (95% confidence interval (95% CI [40.46-43.89])) and mean MCS12 score of 47.13 (95% CI [45.98-48.28]). No difference was found between SF12 scores at 6 and 12 months.
This study pinpoints the persistence of fatigue and a low mental and physical QOL compared to population norms even after 1 year following infection. It also supports the claims of mental or psychological alterations due to infection by this new virus, hence a lower overall QOL in patients.
自至少 2 年前以来，SARS-COV2 大流行一直在全球范围内持续。在严重的情况下，这种感染会引发急性呼吸窘迫综合征和准系统性损伤，伴有广泛的症状。因此，这些患者自然会出现这种感染的长期身体和心理后果。本研究的目的是描述这些患者在感染后 6 个月（M6）和 12 个月（M12）时的健康状况，并比较这些时间点的生活质量（QOL）和疲劳程度。
在兰斯大学医院设立了一项前瞻性队列研究。患者在 M6 和 M12 时进行临床评估。计算了三个评分来描述患者的状况：改良的医学研究理事会评分（mMRC）用于确定呼吸困难状态，疲劳严重程度量表（FSS）和简短表格 12（SF12）用于确定精神和身体的生活质量（MCS12 和 PCS12）。对 M6 和 M12 之间的评分进行描述性分析和比较。
120 名患者完成了两次随访咨询。总体而言，约 40%的患者出现呼吸困难症状。中位数 mMRC 评分为 1 个四分位距（IQR）[0-2]在两次评估中。关于 FSS 评分，35%和 44%的患者在两次随访时均感到疲劳。SF12 的两个评分均低于一般人群的标准评分。6 个月时平均 PCS12 评分为 42.85（95%置信区间（95%CI[41.05-44.65]）），平均 MCS12 评分为 46.70（95%置信区间（95%CI[45.34-48.06]））。12 个月时，平均 PCS12 评分为 42.18（95%置信区间（95%CI[40.46-43.89]）），平均 MCS12 评分为 47.13（95%置信区间（95%CI[45.98-48.28]））。SF12 评分在 6 个月和 12 个月之间没有差异。
本研究指出，即使在感染后 1 年，与人群正常值相比，疲劳和精神及身体生活质量（QOL）仍然持续存在。它还支持因这种新病毒感染而导致的精神或心理改变的说法，因此患者的整体 QOL 较低。
